Hallmarks of 'BRCAness' in sporadic cancers - PubMed (original) (raw)
Review
doi: 10.1038/nrc1457.
Affiliations
- PMID: 15510162
- DOI: 10.1038/nrc1457
Review
Hallmarks of 'BRCAness' in sporadic cancers
Nicholas Turner et al. Nat Rev Cancer. 2004 Oct.
Abstract
Germline mutations in the BRCA1, BRCA2 and Fanconi anaemia genes confer cancer susceptibility, and the proteins encoded by these genes have distinct functions in related DNA-repair processes. Emerging evidence indicates that these processes are disrupted by numerous mechanisms in sporadic cancers. Collectively, there are properties that define 'BRCAness' - that is, traits that some sporadic cancers share with those occurring in either BRCA1- or BRCA2-mutation carriers. These common properties might have important implications for the clinical management of these cancers.
Similar articles
- New complexities for BRCA1 and BRCA2.
Kerr P, Ashworth A. Kerr P, et al. Curr Biol. 2001 Aug 21;11(16):R668-76. doi: 10.1016/s0960-9822(01)00389-x. Curr Biol. 2001. PMID: 11525763 Review. - Current knowledge on the pathophysiology of Fanconi anemia: from genes to phenotypes.
Yamashita T, Nakahata T. Yamashita T, et al. Int J Hematol. 2001 Jul;74(1):33-41. doi: 10.1007/BF02982547. Int J Hematol. 2001. PMID: 11530803 Review. - Biomedicine. D-Day for BRCA2.
Witt E, Ashworth A. Witt E, et al. Science. 2002 Jul 26;297(5581):534. doi: 10.1126/science.1074482. Epub 2002 Jun 13. Science. 2002. PMID: 12065747 No abstract available. - PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, Yu X. Zhang F, et al. Curr Biol. 2009 Mar 24;19(6):524-9. doi: 10.1016/j.cub.2009.02.018. Epub 2009 Mar 5. Curr Biol. 2009. PMID: 19268590 Free PMC article. - Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
Seal S, Barfoot R, Jayatilake H, Smith P, Renwick A, Bascombe L, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N; Breast Cancer Susceptibility Collaboration. Seal S, et al. Cancer Res. 2003 Dec 15;63(24):8596-9. Cancer Res. 2003. PMID: 14695169
Cited by
- Deletions Rate-Limit Breast and Ovarian Cancer Initiation.
Houlahan KE, Bihie M, Contreras JG, Fulop DJ, Lopez G, Huang HH, Van Loo P, Curtis C, Boutros PC, Huang KL. Houlahan KE, et al. bioRxiv [Preprint]. 2024 Oct 21:2024.10.17.618945. doi: 10.1101/2024.10.17.618945. bioRxiv. 2024. PMID: 39484366 Free PMC article. Preprint. - Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials.
Panebianco M, Cereda V, D'Andrea MR. Panebianco M, et al. Explor Target Antitumor Ther. 2024;5(5):997-1010. doi: 10.37349/etat.2024.00260. Epub 2024 Aug 2. Explor Target Antitumor Ther. 2024. PMID: 39351435 Free PMC article. Review. - DNA damage response in breast cancer and its significant role in guiding novel precise therapies.
Li J, Jia Z, Dong L, Cao H, Huang Y, Xu H, Xie Z, Jiang Y, Wang X, Liu J. Li J, et al. Biomark Res. 2024 Sep 27;12(1):111. doi: 10.1186/s40364-024-00653-2. Biomark Res. 2024. PMID: 39334297 Free PMC article. Review. - The coexistence of a BRCA2 germline and a DICER1 somatic variant in two first-degree cousins suggests their potential synergic effect.
Del Baldo G, Mastronuzzi A, Cipri S, Agolini E, Matraxia M, Novelli A, Cacchione A, Serra A, Carai A, Boccuto L, Colafati GS, Di Paolo PL, Miele E, Barresi S, Alaggio R, Rossi S, Giovannoni I. Del Baldo G, et al. Sci Rep. 2024 Sep 13;14(1):21435. doi: 10.1038/s41598-024-71667-x. Sci Rep. 2024. PMID: 39271738 Free PMC article. - NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy.
Xiao M, Yang J, Dong M, Mao X, Pan H, Lei Y, Tong X, Yu X, Yu X, Shi S. Xiao M, et al. Cell Death Dis. 2024 Aug 26;15(8):620. doi: 10.1038/s41419-024-06984-0. Cell Death Dis. 2024. PMID: 39187531 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous